Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.39 |
| ▸ | TLR2 | O60603 | 7/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.32 |
| ▸ | LPAR4 | Q99677 | 2/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24968569 | 1.00 | LPAR1 (0.39) | LPAR1LPAR3LPAR2TLR2USP2 | |
| SCHEMBL24968570 | 1.00 | LPAR1 (0.39) | LPAR1LPAR3LPAR2TLR2USP2 | |
| SCHEMBL25873463 | 0.91 | LPAR1 (0.36) | LPAR1LPAR3LPAR2TLR2USP2 | |
| SCHEMBL24968555 | 0.91 | LPAR1 (0.36) | LPAR1LPAR3LPAR2TLR2USP2 | |
| SCHEMBL25869120 | 0.90 | DNM1 (0.37) | LPAR1LPAR3TLR2 | |
| SCHEMBL25869121 | 0.90 | DNM1 (0.37) | LPAR1LPAR3TLR2 | |
| SCHEMBL25869114 | 0.90 | DNM1 (0.37) | LPAR1LPAR3TLR2 | |
| SCHEMBL25869127 | 0.90 | DNM1 (0.37) | LPAR1LPAR3TLR2 | |
| SCHEMBL25869116 | 0.90 | DNM1 (0.37) | LPAR1LPAR3TLR2 | |
| SCHEMBL25873525 | 0.89 | TLR2 (0.32) | LPAR1LPAR3LPAR2TLR2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233468-A1 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | CETP, NPC1, LCAT | LPAR1 191/4885LPAR3 201/4885LPAR2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.